- Home
- HTLD vs EYPT Comparison
HTLD vs EYPT Comparison
Compare HTLD & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HTLD | EYPT |
|---|---|---|
| Founded | 1978 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | HTLD | EYPT |
|---|---|---|
| Price | $15.12 | $12.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $11.50 | ★ $31.80 |
| AVG Volume (30 Days) | 547.6K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $805,709,000.00 | $7,539,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.36 | $3,115.57 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $9.41 |
| 52 Week High | $16.64 | $19.11 |
Technical Indicators
Market Signals| Indicator | HTLD | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.70 | 42.78 |
| Support Level | $14.24 | $11.81 |
| Resistance Level | $15.58 | $14.12 |
| Average True Range (ATR) | 0.46 | 1.09 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 64.76 | 8.65 |
Price Performance
Historical ComparisonAbout HTLD Heartland Express Inc.
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.